The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single-institution, retrospective examination of new contrast enhancement, progression, and pseudoprogression in IDH mutant glioma.
 
Ethan Wetzel
No Relationships to Disclose
 
Blaine S.C. Eldred
No Relationships to Disclose
 
Vicki Liu
No Relationships to Disclose
 
Serendipity Zapanta Rinonos
No Relationships to Disclose
 
Negar Khanlou
No Relationships to Disclose
 
Linda M. Liau
Leadership - ClearPoint Neuro, Inc.
Stock and Other Ownership Interests - ClearPoint Neuro, Inc.
Research Funding - Arbor Pharmaceuticals; Northwest Biotherapeutics
 
Phioanh Leia Nghiemphu
No Relationships to Disclose
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Break Through Cancer; Global Coalition for Adaptive Research
 
Benjamin M. Ellingson
Consulting or Advisory Role - Alpheus Medical; Chimerix; Ellipses Pharma; Global Coalition for Adaptive Research; Imaging Endpoints; ImmunoGenesis; Janssen; Kazia Therapeutics; Medicenna; MedQIA; Monteris Medical; Neosoma; SERVIER; Siemens; Sumitomo Dainippon Pharma Oncology; VBL Therapeutics
Research Funding - Janssen; Siemens
Travel, Accommodations, Expenses - Siemens
 
Albert Lai
No Relationships to Disclose